A Phase 3 interventional study of BMS-986205 and Nivolumab in Melanoma and Skin Cancer, sponsored by Bristol-Myers Squibb. Completed at 63 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-07-09.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Melanoma by Bristol-Myers Squibb — 3 open to participants now, 9 under way, 3 of them phase 3. Melanoma · Bristol-Myers Squibb.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 59th largest by enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2017, is one of 21 in phase 3, and was the 79th registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →3 of the 111 studies in Melanoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Belgium, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 5 more countries
Ages 18+
Bristol-Myers Squibb · Sites in India
Ages 12+
By country, each count listing its studies:
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 33 · Phase 3 23 · Phase 4 1
First in 2002; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 107 across the 75 interventional studies, 366 across the 32 observational. Of the 90 that completed or were terminated, 41 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Melanoma by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04550247Bristol-Myers SquibbA Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France | 2027-03-15 |
Add it to your calendar (.ics) → With an account.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Specified dose on specified day Participants will no longer receive BMS-986205 Placebo
Biological: Nivolumab · Drug: Placebo
Specified dose on specified day. Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion
Drug: BMS-986205 · Biological: Nivolumab
specified dose on specified day
Specified dose on specified day
Also known as: BMS-936558
Specified dose on specified day
Also known as: BMS-986205 matching placebo
Number of Participants Experiencing Adverse Events
Number of participants experiencing different types of Adverse Events, including Death, Any cause Adverse Events (AEs), Drug-related AEs, Any cause Serious Adverse Events (SAEs), Drug-related SAEs, SAEs leading to discontinuation, and Drug-related Non-serious AEs leading to discontinuation
Time frame: From first dose to 30 days following last dose (up to approximately 25 months)
| Milestone | Nivolumab + BMS-986205 | Nivolumab |
|---|---|---|
| Started | 10 | 10 |
| Completed | 2 | 1 |
| Not completed | 8 | 9 |
| Withdrew: Disease progression | 4 | 6 |
| Withdrew: Study drug toxicity | 1 | 0 |
| Withdrew: Participant request to discontinue treatment | 0 | 1 |
| Withdrew: Participant withdrew consent | 1 | 0 |
| Withdrew: Other reasons | 2 | 2 |
Number of participants experiencing different types of Adverse Events, including Death, Any cause Adverse Events (AEs), Drug-related AEs, Any cause Serious Adverse Events (SAEs), Drug-related SAEs, SAEs leading to discontinuation, and Drug-related Non-serious AEs leading to discontinuation
| Participants | Nivolumab + BMS-986205 | Nivolumab |
|---|---|---|
| Deaths | 0 | 0 |
| Any cause SAEs (any grade) | 3 | 3 |
| Drug-related SAEs (any grade) | 1 | 0 |
| SAEs leading to discontinuation | 1 | 0 |
| Any cause AEs (any grade) | 10 | 9 |
| Drug-related AEs (any grade) | 9 | 7 |
| Drug-Related Non-serious AEs leading to discontinuation | 0 | 0 |
Collected over All-cause mortality was assessed from first dose to approximately 300 days following last dose. Serious adverse events and non-serious adverse events above 5% were assessed from first dose to 100 days following last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab + BMS-986205 | 1/10 (10%) | 4/10 (40%) | 10/10 (100%) |
| Nivolumab | 3/10 (30%) | 4/10 (40%) | 9/10 (90%) |
| Event | Nivolumab + BMS-986205 | Nivolumab |
|---|---|---|
| ConstipationGastrointestinal disorders | 1/10 | 0/10 |
| VomitingGastrointestinal disorders | 1/10 | 0/10 |
| Gastroenteritis viralInfections and infestations | 1/10 | 0/10 |
| Lower respiratory tract infectionInfections and infestations | 0/10 | 1/10 |
| PneumoniaInfections and infestations | 0/10 | 1/10 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 1/10 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/10 | 1/10 |
| Renal failureRenal and urinary disorders | 1/10 | 0/10 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/10 | 1/10 |
| Event | Nivolumab + BMS-986205 | Nivolumab |
|---|---|---|
| NauseaGastrointestinal disorders | 5/10 | 4/10 |
| AstheniaGeneral disorders | 5/10 | 2/10 |
| Decreased appetiteMetabolism and nutrition disorders | 3/10 | 2/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/10 | 3/10 |
| ConstipationGastrointestinal disorders | 2/10 | 1/10 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 2/10 |
| VomitingGastrointestinal disorders | 1/10 | 2/10 |
| FatigueGeneral disorders | 2/10 | 2/10 |
| Influenza like illnessGeneral disorders | 2/10 | 1/10 |
| Lower respiratory tract infectionInfections and infestations | 0/10 | 2/10 |
| Age, Categorical(Participants) | Nivolumab + BMS-986205 | Nivolumab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 6 | 10 |
| >=65 years | 6 | 4 | 10 |
| Sex: Female, Male(Participants) | Nivolumab + BMS-986205 | Nivolumab | Total |
|---|---|---|---|
| Female | 4 | 4 | 8 |
| Male | 6 | 6 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab + BMS-986205 | Nivolumab | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 6 | 5 | 11 |
| Unknown or Not Reported | 4 | 4 | 8 |
| Race (NIH/OMB)(Participants) | Nivolumab + BMS-986205 | Nivolumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 10 | 8 | 18 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Jul 2020, 31 months.
Results were first posted in Jul 2021, 1 year after primary completion.
Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 31 months is below that.
Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linrodostat